Entera Bio

Entera Bio Intangible Assets

The Intangible Assets of Entera Bio (ENTX) as of Oct 8, 2026 is 610,000.00 USD. In the previous year, Intangible Assets was 650,000.00 USD — a change of -6.15% (lower).

Intangible Assets

610,000.00USD

YoY

-6.15%

Last updated:

Intangible Assets of Entera Bio is 2019 610,000.00 USD. Intangible Assets of Entera Bio was 2018 650,000.00 USD. It decreases by -6.15% lower compared to the previous year.

The Entera Bio Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2015
650,000.00 USD
Jan 1, 2016
650,000.00 USD
Jan 1, 2017
650,000.00 USD
Jan 1, 2018
650,000.00 USD
Jan 1, 2019
610,000.00 USD
The Entera Bio Intangible Assets history
YEARIntangible AssetsYoY
610,000.00USD-6.15%
650,000.00USD0.00%
650,000.00USD0.00%
650,000.00USD0.00%
650,000.00USD—
Access this data via the Eulerpool API
Get Free API Key

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Intangible Assets of Entera Bio is 610,000.00 USD in 2019.

Intangible Assets of Entera Bio changed from 650,000.00 USD to 610,000.00 USD, representing a -6.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Entera Bio historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Entera Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Entera Bio